All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
STARGLO trial of glofitamab: primary endpoint met in R/R DLBCL
On April 15, 2024, it was announced that the phase III STARGLO trial (NCT04408638) assessing glofitamab, a CD20 × CD3 T-cell engaging bispecific antibody, plus gemcitabine and oxaliplatin vs rituximab plus gemcitabine and oxaliplatin met its primary endpoint of overall survival. Glofitamab in combination with gemcitabine and oxaliplatin demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of therapy and were not candidates for autologous stem cell transplant. The safety profile of the combination was consistent with the known safety profiles of the individual treatments.
Glofitamab previously received accelerated approval from the U.S. Food and Drug Administration (FDA) and conditional marketing authorization from the European Commission (EC) for the treatment of patients with R/R DLBCL after two or more lines of systemic therapy.
These encouraging data show that glofitamab in combination with gemcitabine and oxaliplatin has the potential to improve survival outcomes in earlier lines of treatment for patients with R/R DLBCL, who currently have limited options.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?
